Alimta by Eli Lilly and Co for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval
Alimta is under clinical development by Eli Lilly and Co and currently in Phase II for Triple-Negative Breast Cancer (TNBC). According to GlobalData, Phase II drugs for Triple-Negative Breast Cancer (TNBC) have a 24% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData's report assesses how Alimta's drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.Alimta overviewPemetrexed disodium hydrate (Alimta / Trenuvis / Reladdin) is a drug that belongs to a class of chemotherapeutic drugs known as folate antimetabolites. It is the disodium salt of a synthetic pyrimidine-based antifolate. It is formulated as lyophilized powder for solution for intravenous route of administration. It is indicated in combination with cisplatin is indicated for the treatment of chemotherapy-naive patients with unresectable malignant pleural mesothelioma. Alimta in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. It is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy. Alimta is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology and, Alimta in combination with carboplatin and pembrolizumab is indicated for the initial treatment of patients with metastatic, non-squamous, non-small cell lung cancer. The drug candidate is under development for the treatment of recurrent or metastatic triple negative breast cancer, chordoma and metastatic urothelial tract cancer. It was also under development for the treatment of advanced colorectal cancer and advanced gastric carcinoma, advanced or metastatic bladder cancer and cervical cancer, head and neck squamous cell carcinoma and HER-2 negative breast cancer. It was under development for the treatment of recurrent head and neck cancer.Eli Lilly and Co overviewEli Lilly and Co (Lilly) is a healthcare company that is engaged in the discovery, development, and marketing of human healthcare products. The company offers medicines for cardiovascular conditions, diabetes, endocrinology, cancer, neurological problems, autoimmune disorders, men's health, and musculoskeletal problems. The company distributes its pharmaceutical health products through independent wholesale distributors. Lilly conducts research and development activities to discover and deliver innovative medicines. It also promotes products through sales representatives and marketing agreements with other pharmaceutical companies. The company also offers its products in North America, South America, Europe, the Middle East, Africa and Asia-Pacific. Lilly is headquartered in Indianapolis, Indiana, the US. For a complete picture of Alimta's drug-specific PTSR and LoA scores, buy the report here.
Alimta is under clinical development by Eli Lilly and Co and currently in Phase II for Triple-Negative Breast Cancer (TNBC).
What's Your Reaction?
